Anteris Advances DurAVR Trial with $320M Raise and Medicare Coverage

• H1 2026 revenue up 28% to $1.5 million
• Loss after tax widened 20% to $51.7 million
• R&D expenses surge with manufacturing scale-up and PARADIGM Trial
• Raised $320 million in January via public offering and Medtronic placement
• Secured U.S. Medicare reimbursement, initiated U.S. patient enrolment

Financials Reflect Heavy Investment in DurAVR Development

Anteris Technologies Global Corp. (ASX:AVR, NASDAQ: AVR) posted a $51.7 million loss for the six months ended June 30, 2026, widening 20% from the prior year as it accelerated research and development and clinical trial activities for its DurAVR® Transcatheter Heart Valve (THV). Revenue rose 28% to $1.5 million, largely from increased sales of regenerative tissue products to 4C Medical Technologies.

The loss reflects a 24% jump in R&D expenses to $40.8 million, driven by scaling manufacturing capabilities, process validation, and expanding the clinical team supporting the pivotal PARADIGM Trial. Selling, general and administrative costs also climbed 43% to $15.3 million, reflecting headcount growth and operational expansion.

$320 Million Capital Raise Fuels Development and Trial Expansion

In January 2026, Anteris completed a significant capital raise comprising a $230 million underwritten public offering and a $90 million private placement to Medtronic, netting approximately $320 million. This influx boosted cash reserves to $260.9 million by June 30, providing a robust runway for clinical and manufacturing scale-up.

In May 2026, the company also launched an at-the-market equity offering program allowing it to raise up to $250 million over time, underscoring its intent to maintain funding flexibility as it advances commercialization.

Clinical Progress Accelerates with Medicare Coverage and U.S. Enrollment

The quarter saw key advances in the PARADIGM Trial, a global randomized controlled study comparing the DurAVR THV to existing transcatheter aortic valve replacements. In April, Anteris secured U.S. Medicare reimbursement eligibility under CMS National Coverage Determination 20.32, a critical milestone enabling reimbursement for eligible procedures at U.S. trial sites.

Following this, patient recruitment in the U.S. began in May, complementing ongoing enrolment in Europe, including Denmark, the Netherlands, Canada, and France where regulatory clearance was obtained. The trial aims to enroll approximately 1,000 patients to demonstrate non-inferiority on a composite endpoint of mortality, stroke, and cardiovascular hospitalization at one year.

Operational and Governance Enhancements Support Commercialisation Pathway

Alongside clinical progress, Anteris expanded its Board of Directors, appointing Susan Knight and Stephen Denaro to bolster governance and financial expertise as it moves closer to potential market approval. Manufacturing capacity is being scaled in new clean room facilities in the U.S. and Australia to support trial supply and future commercial demand.

The company continues to consolidate its investment in v2vmedtech, despite ceasing further funding, maintaining control through board appointments. Material weaknesses in internal controls over financial reporting remain but remediation efforts are underway.

Looking Ahead: Trial Milestones and Capital Management

Anteris expects to continue incurring losses as it progresses the PARADIGM Trial and prepares for Premarket Approval (PMA) submissions in the U.S. and CE Mark approval in Europe. The company believes its current cash position will support operations for at least the next 12 months, but acknowledges the need for further capital to fund commercialization efforts.

Investors will be watching closely for patient enrolment rates, clinical data readouts, and regulatory milestones that will shape the commercial viability of the DurAVR THV. How Anteris manages its capital and operational scale in this critical phase will be key to its future trajectory.

Bottom Line?

Anteris is investing heavily to bring its DurAVR heart valve to market, with strong capital backing and regulatory progress, but continued losses and clinical uncertainties remain significant hurdles.

Questions in the middle?

• Will patient recruitment pace in the PARADIGM Trial meet expectations to support timely PMA submission?
• How effectively can Anteris translate Medicare reimbursement coverage into broader U.S. trial site activation and adoption?
• What impact will ongoing remediation of internal control weaknesses have on financial reporting reliability?